A5062084501- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Medical Imaging Techniques and Applications
- Nutrition, Health and Food Behavior
- Neurological and metabolic disorders
- Parkinson's Disease Mechanisms and Treatments
- Epilepsy research and treatment
- Head and Neck Surgical Oncology
- Regulation of Appetite and Obesity
- S100 Proteins and Annexins
- Cancer-related cognitive impairment studies
- Functional Brain Connectivity Studies
- Neuroscience and Neuropharmacology Research
- Neurological disorders and treatments
- Nutritional Studies and Diet
- Meningioma and schwannoma management
- Glioma Diagnosis and Treatment
Korea Institute of Radiological and Medical Sciences
2017-2021
Barro Colorado Island
2017
University of Hong Kong
2013
Chinese University of Hong Kong
2013
We compared levels of Aβ by self-standard in plasma using an interdigitated microelectrode sensor to detect Alzheimer disease.
Alzheimer disease (AD) diagnosis is confirmed using a medley of modalities, such as the detection amyloid-β (Aβ) neuritic plaques and neurofibrillary tangles with positron electron tomography (PET) or appraisal irregularities in cognitive function examinations. Although these methods have been efficient confirming AD pathology, rising demand for earlier intervention during pathogenesis has led researchers to explore diagnostic potential fluid biomarkers cerebrospinal (CSF) plasma. Since CSF...
Abstract 123 I‐FP‐CIT and 18 F‐FP‐CIT are radiotracers which widely used to diagnose Parkinson's disease (PD). However, our knowledge, no studies date have made head‐to‐head comparisons between F‐FP‐CIT. Therefore, in this study, SPECT/CT was compared with PET/CT the same cohort of subjects. Patients PD essential tremor (ET) underwent PET/CT. Visual semiquantitative analyses were conducted. The specific binding ratio (SBR) putamen caudate (PCR) subjects who analysis showed that striatal...
As a new beta amyloid (Aβ) positron emission tomography (PET) tracer, 18F-FC119S has shown higher cortical uptake in patients with Alzheimer's disease (AD) than that healthy control subjects without adverse effects previous preliminary study. The aim of this study was to compare PET and 11C-PiB (HC) subjects, mild cognitive impairment (MCI) patients, AD patients. A total 48 including 28 HC 10 MCI underwent static (30 minutes after intravenous [i.v.] injection) (40 i.v. on the same day. Both...
For the diagnosis of mild cognitive impairment (MCI) and Alzheimer disease (AD), variable neuroimaging neuropsychological tests have been used. We aimed to evaluate correlation domain with new amyloid positron emission tomography (PET) study validate availability PET tracer.We enrolled 20 patients who underwent C-PiB-PET/CT, tracer F-FC119S PET/CT from November, 2014 July, 2015. Among them, 10 were diagnosed AD MCI. The current version Seoul Neuropsychological Screening Battery (SNSB) II was...
Abstract A 76-year-old woman underwent 18 F-florapronol ( F-FC119S, an amyloid β imaging PET agent) PET, owing to cognitive impairment. images revealed incidental uptake in the right frontal lobe. well-enhancing extra-axial mass lobe was observed on MRI scans, suggesting a meningioma. After excision of tumor, biopsy results confirmed it as meningothelial
The aim of this study was to determine the diagnostic performance and safety a new ¹⁸F-labeled amyloid tracer, ¹⁸F-FC119S.This prospectively recruited 105 participants, comprising 53 with Alzheimer's disease (AD) patients, 16 patients dementia other than AD (non-AD), 36 healthy controls (HCs). In first screening visit, Seoul Neuropsychological Screening Battery cognitive function test given group, while HC subjects completed Korean version Mini Mental State Examination. Individuals underwent...